KRAS and non-small cell lung carcinoma: These data are in line with other studies in Caucasian populations, where, e.g., plasma cfDNA from 23.4% newly diagnosed metastatic NSCLC patients were mutated for EGFR and 22.6% had detectable KRAS [32,33].